Gaucher disease type 2

Gaucher disease is a lysosomal storage disorder. Lysosomes are the parts of a cell that break down and recycle used material. When the enzyme glucocerebrosidase is missing or very weak, fatty substances build up in cells throughout the body, including the brain.

There are three main types. Type 1 usually does not affect the brain. Type 3 affects the brain more slowly and usually starts in childhood. Type 2, also called acute neuronopathic or infantile Gaucher disease, is the most severe. In France, it is also the rarest type: fewer than 1 in 100 people with Gaucher disease have type 2.

The most severe form of all is called perinatal lethal Gaucher disease. It starts before birth. A baby may have severe swelling from fluid (hydrops fetalis) or dry, peeling skin at birth. Most babies with this form live only a few days.

Type 2 is caused by changes in both copies of the GBA1 gene, which holds the instructions for the glucocerebrosidase enzyme. In type 2, the gene changes often leave very little working enzyme. Babies with no enzyme activity at all tend to have the earliest and most severe disease.

It is inherited in an autosomal recessive pattern. Each parent usually carries one changed copy and has no symptoms. When both parents are carriers, each pregnancy has a 1 in 4 chance of an affected baby. Rarely, the pattern is different, for example when a gene change arises new in the child. A genetic counselor can explain the real chance for a future pregnancy.

Nothing a parent did caused it, and it is not contagious. Type 2 is found in every ethnic group. Unlike type 1, it is not more common in Ashkenazi Jewish families.

Many babies seem healthy at birth and then change quickly in the first months. Others show signs at or before birth. Early signs can include a large spleen and liver, low platelets, feeding trouble and poor weight gain.

The disease damages the brainstem, the part of the brain that controls swallowing and breathing. Babies may have trouble sucking and swallowing, choking spells, pauses in breathing, and noisy breathing from spasms of the voice box (laryngospasm). Many hold the head and neck bent backward, have stiff muscles and crossed eyes (strabismus), and later develop seizures.

Lung problems are common, often because food or saliva goes into the lungs. Choking spells and breathing pauses tend to happen more often as the disease progresses.

Doctors often first suspect it in a baby with a large spleen and liver, low platelets, feeding trouble or poor weight gain. A neck held stiffly backward is another clue. Some babies are first noticed because of shiny, peeling skin at birth or fluid swelling before birth (hydrops fetalis). In an international study, the median age at the first brain or nerve sign was 4 months, and the median age at diagnosis was 8 months.

The key test measures the enzyme glucocerebrosidase in white blood cells or skin cells. It needs cells that have a nucleus, so it cannot be done on plasma or red cells. Genetic testing of the GBA1 gene confirms the diagnosis. The gene is hard to read, because a nearby look-alike gene (pseudogene) can confuse results, so the whole gene has to be checked carefully.

Telling type 2 apart from type 3 can be hard at first, because enzyme and gene results overlap. How fast the signs change over time helps. Babies with type 2 do not have the N370S gene change. As of a 2025 report, six U.S. states screened all newborns for Gaucher disease. In New Jersey, two babies with type 2 were found this way between 2019 and 2023.

No approved medicine stops or slows the brain disease of type 2. French national guidance (2025) says there is no specific treatment for type 2, so care focuses on symptoms and comfort (palliative care).

Care is shaped around the baby’s comfort and needs. A feeding tube, through the nose or directly into the stomach (gastrostomy), can make feeding safer. Medicines can ease stiffness, irritability, extra saliva and seizures. Some families choose a breathing tube in the neck (tracheostomy). It may lengthen life, but specialists say that choosing not to have one can also be a very reasonable decision.

Enzyme replacement therapy with imiglucerase is approved for the non-brain problems of types 1 and 3. In type 2, it can shrink the spleen and liver and improve blood counts. But the enzyme does not cross into the brain, and there is no evidence that it slows the brain disease. It is not approved for type 2. Some care teams offer it for a time while it is unclear whether a baby has type 2 or type 3. Others use it to ease discomfort from a very large spleen.

A donor stem cell transplant has been tried in only a handful of babies. A 2020 study looked back at 23 children with type 2. Three had a bone marrow transplant, and all three died, at 15, 51 and 55 months of age. The study’s authors wrote that current treatments appear to lengthen life but do not change the brain disease. Specialists also point out that a very ill baby may face a transplant’s risks far from home and family.

Research continues. A one-time gene therapy called LY3884961 (formerly PR001) is given into the fluid around the brain. It was tested in 7 infants in the United States and United Kingdom, and as of September 2026 the trial was no longer enrolling. A smaller early trial of another gene therapy has been listed in China. Some doctors have tried high doses of ambroxol, a mucus-loosening medicine, alongside enzyme therapy. Its effect seems to depend on the baby’s gene changes. A 2026 report described two children treated this way. One was developing normally at age 6½. The other had moderate to severe delays but kept making progress. Ambroxol is not approved for Gaucher disease and is still being studied.

Hearing this diagnosis for a baby is devastating. Many babies seemed healthy at first, and parents may feel shock, grief and sometimes guilt, even though nothing they did caused it. Specialists say parents need honest information, kindness and ongoing counseling from the care team.

Specialists say type 2 is especially suited to palliative care, which focuses on comfort and quality of life. It helps families set goals that fit their own values, culture and beliefs. Hospice services, counseling and support groups can help, and counseling for parents and support for brothers and sisters continue after a child dies.

In one study of 23 families, many parents reported mental health struggles and difficulty communicating with medical staff. Specialists say support works best when a team of different specialists shares the care.

Genetic counseling helps parents understand the chances in a future pregnancy and the options, such as testing during pregnancy or testing embryos before pregnancy (preimplantation testing).

A donor is not part of the usual care for type 2. A transplant has not been shown to help the brain disease, so it is not part of standard care.

Parents and brothers or sisters may be tested for the family’s gene changes. This is for family planning and to find other affected children, not to find a donor.

A shortage of registry donors is not what holds back care for type 2. Treatments that reach the brain are the real need. Joining a registry still helps the many patients with other conditions who need an unrelated donor.

This is one of the hardest diagnoses a family can face. Type 2 gets worse quickly, and most children die in infancy or early childhood. French national guidance (2025) says the disease usually leads to death within the first 3 years of life.

Enzyme therapy, feeding tubes and breathing tubes can lengthen life for some children, but they do not change the brain disease. Some children diagnosed with type 2 now live into childhood. Researchers are studying whether this reflects newer care or a slightly milder form of the disease.